{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:23:36Z","timestamp":1784136216774,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ejca.2015.04.017","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T17:23:04Z","timestamp":1431364984000},"page":"1467-1475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease"],"prefix":"10.1016","volume":"51","clinical-trial-number":[{"clinical-trial-number":"nct00321464","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00330759","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ingo J.","family":"Diel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison T.","family":"Stopeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Vadhan-Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Steger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2015.04.017_b0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1026597816193","article-title":"Hypercalcemia of malignancy","volume":"1","author":"Grill","year":"2000","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"10.1016\/j.ejca.2015.04.017_b0010","first-page":"1551","article-title":"Cancer-induced hypercalcemia","volume":"29","author":"Lumachi","year":"2009","journal-title":"Anticancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2015.04.017_b0015","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.2215\/CJN.02470312","article-title":"Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia","volume":"7","author":"Rosner","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.ejca.2015.04.017_b0020","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.2174\/092986711796642490","article-title":"Malignant hypercalcemia","volume":"18","author":"Basso","year":"2011","journal-title":"Curr Med Chem"},{"issue":"1","key":"10.1016\/j.ejca.2015.04.017_b0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semnephrol.2003.08.015","article-title":"Hypercalcemia of malignancy","volume":"24","author":"Body","year":"2004","journal-title":"Semin Nephrol"},{"issue":"4","key":"10.1016\/j.ejca.2015.04.017_b0030","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1097-0142(19930215)71:4<1309::AID-CNCR2820710423>3.0.CO;2-M","article-title":"Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center","volume":"71","author":"Vassilopoulou-Sellin","year":"1993","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2015.04.017_b0035","first-page":"244","article-title":"Cancer-related hypercalcemia","volume":"56","author":"Seccareccia","year":"2010","journal-title":"Can Fam Physician"},{"issue":"6","key":"10.1016\/j.ejca.2015.04.017_b0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.7-6-481","article-title":"The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy","volume":"7","author":"Major","year":"2002","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ejca.2015.04.017_b0045","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2015.04.017_b0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-149-4-200808190-00007","article-title":"Narrative review: furosemide for hypercalcemia: an unproven yet common practice","volume":"149","author":"LeGrand","year":"2008","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.ejca.2015.04.017_b0055","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2015.04.017_b0060","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3390\/ijerph7052337","article-title":"Medical applications and toxicities of gallium compounds","volume":"7","author":"Chitambar","year":"2010","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"10.1016\/j.ejca.2015.04.017_b0065","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"issue":"16","key":"10.1016\/j.ejca.2015.04.017_b0070","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"issue":"9768","key":"10.1016\/j.ejca.2015.04.017_b0075","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2015.04.017_b0080","series-title":"XGEVA\u00ae prescribing information","year":"2012"},{"issue":"3","key":"10.1016\/j.ejca.2015.04.017_b0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.ejca.2015.04.017_b0090","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.04.017_b0095","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2015.04.017_b0100","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox\u2019s regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"issue":"3","key":"10.1016\/j.ejca.2015.04.017_b0105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/era.11.204","article-title":"Denosumab for the management of bone disease in patients with solid tumors","volume":"12","author":"Body","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.ejca.2015.04.017_b0110","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.ejca.2015.04.017_b0115","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1210\/en.2004-1583","article-title":"The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy","volume":"146","author":"Morony","year":"2005","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.ejca.2015.04.017_b0120","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s005200050008","article-title":"Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia","volume":"8","author":"Body","year":"2000","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2015.04.017_b0125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650050304","article-title":"Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone","volume":"5","author":"Thiebaud","year":"1990","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.1016\/j.ejca.2015.04.017_b0130","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/0277-5379(91)90431-C","article-title":"Parathyroid hormone-related protein(50\u201369) and response to pamidronate therapy for tumour-induced hypercalcaemia","volume":"27","author":"Dodwell","year":"1991","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2015.04.017_b0135","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2265.1994.tb02569.x","article-title":"Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcaemia in two hospital populations","volume":"41","author":"Walls","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"258","key":"10.1016\/j.ejca.2015.04.017_b0140","first-page":"825","article-title":"Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia","volume":"68","author":"Ralston","year":"1988","journal-title":"Q J Med"},{"issue":"16","key":"10.1016\/j.ejca.2015.04.017_b0145","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial \u2013 The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.ejca.2015.04.017_b0150","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915003731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915003731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T13:58:33Z","timestamp":1537624713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915003731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0959804915003731"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.04.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}